Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JANUARY 2016. Refer to TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | enzalutamide (Xtandi®) | ||
| Formulation | 40 mg capsule | ||
| Reference number | 1773 | ||
| Indication | Treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated |
||
| Company | Astellas Pharma Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 1415 | ||
| NMG meeting date | 15/04/2015 | ||
| AWMSG meeting date | 15/07/2015 | ||
| Ratification by Welsh Government | 01/09/2015 | ||
| Date of issue | 04/09/2015 | ||
| NICE guidance | |||
| Commercial arrangement | PAS | ||
| Further information Technologies recommended by NICE that include a commercial arrangement |
|||